In many parts of the world, atherosclerosis is one of the diseases responsible for a large number of cases of premature death.

Six years ago, a handful of researchers at Lund University in Sweden started taking an interest in how to make it easier to recognise unstable plaques that in worst case scenarios rupture and cause heart attacks or strokes.

When Tobias Erlöv, who at the time was a doctoral student in biomedical engineering at the Lund Faculty of Engineering, discovered that there is a fairly simple mathematical calculation that can be used to interpret ultrasound signals and thereby figure out whether the plaque in the carotid artery is harmful or not, the researchers were somewhat surprised.

Vascular surgery is currently only performed if there is excessive blockage to the blood flow, due too large plaques. However, determining whether or not the plaque is unstable cannot be done by simply studying flow rates and plaque sizes – knowing the type of cell concerned is more important.

Simply put, harmless plaques consist of connective tissue and smooth muscle cells. Harmful plaques consist of fat (lipids) and macrophages. Unstable plaques can also involve bleeding.

“We have shown that there is a strong correlation between changes in the centre frequency and the size of the reflecting particles. The more harmful substances, the greater the so-called centre frequency shift”, says Tobias Erlöv, who is currently continuing his research at the Department of Biomedical Engineering.

The method can become useful to identify patients at risk of developing acute cardiovascular diseases, but also to follow up after surgery where plaque has already been removed.

In the future, ultrasound scans of the carotid artery will lead to the ability to perform surgery at an earlier stage in some cases, and the ability to avoid surgery completely in others.

People with cardiovascular diseases, and diabetics who risk developing them, can benefit from this new and accurate method.

“Ultrasound enables you to screen a larger population, and that in turn means that life-threatening cardiovascular diseases can be detected at an earlier stage”, says Magnus Cinthio, senior lecturer in biomedical engineering and one of the researchers leading the work.

“Another advantage is that the method is inexpensive and completely harmless to patients”, says Tobias Erlöv.

More studies are needed before the innovation can be picked up by ultrasound manufacturers and used in healthcare facilities. These studies are already underway, including within the European research collaboration Summit that is currently studying 1 500 patients.

Learn more, contact

Magnus Cinthio, senior lecturer at the Department of Biomedical Engineering

Tel: +46 46 222 97 10, +46 705 09 38 10
Email: magnus [dot] cinthio [at] bme [dot] lth [dot] se (magnus[dot]cinthio[at]bme[dot]lth[dot]se)

Tobias Erlöv, researcher at the Department of Biomedical Engineering
Tel: +46462227691, +46 737 02 65 16
Email: tobias [dot] erlov [at] bme [dot] lth [dot] se

Jan Nilsson, professor at the Experimental Cardiovascular Research Unit
Tel: +46 40391230, +46 733 39 12 30
Email: jan [dot] nilsson [at] med [dot] lu [dot] se

Isabel Goncalves, senior lecturer at the Experimental Cardiovascular Research Unit
Tel: +46 40 39 12 07, +46 40 33 68 52
Email: isabel [dot] goncalves [at] med [dot] lu [dot] se (isabel[dot]goncalves[at]med[dot]lu[dot]se)